Another busy IPO week, headlined by the largest offering since 2011, suggests the new offerings window has opened at last, at least in the U.S. Two companies priced their offerings, three set their price ranges and four jumped in line with filings.

The sector has seen several strong quarters of public market financings, including $2.3 billion raised by biotechs via 31 follow-on deals in 1Q13. However, companies and investors have been waiting for an IPO window to materialize (see BioCentury, April 1).